醋酸环丙孕酮治疗性早熟。

Cyproterone acetate treatment in precocious puberty.

作者信息

Lorini R, Colombo A, Ugazio A G, Salvatoni A, Cisternino M, Larizza D, Polito E, Monafo V, Bozzola M, Severi F

出版信息

J Endocrinol Invest. 1981 Jul-Sep;4(3):263-70. doi: 10.1007/BF03349442.

Abstract

Seven girls with precocious puberty, idiopathic in 6 and associated with the McCune Albright syndrome in 1, were treated with 70 mg/M2/die of cyproterone acetate (CPA) for 11 to 36 months. Before and during treatment clinical parameters (weight, height, bone age, height velocity, prediction of adult height and pubertal development) were evaluated and plasma hormone assays in basal conditions (LH, FSH, 17 beta-estradiol, progesterone, testosterone, PRL, ACTH and cortisol) and after stimulation (LH, FSH, cortisol, GH) were carried out to assess the efficacy and eventual side effects of CPA. The regression observed in the clinical signs of puberty was considered satisfactory and the increase observed in the developmental quotient indicated an improved prognosis for adult height. No symptoms of adrenal insufficiency were observed but an adrenal suppressive effect of CPA was evident from the response to insulin hypoglycemia observed in 4 patients.

摘要

七名性早熟女孩接受了醋酸环丙孕酮（CPA）治疗，剂量为70mg/M²/天，治疗时间为11至36个月。其中6名女孩性早熟病因不明，1名女孩与McCune-Albright综合征相关。治疗前和治疗期间评估了临床参数（体重、身高、骨龄、身高增长速度、成人身高预测和青春期发育），并进行了基础状态下（促黄体生成素、促卵泡生成素、17β-雌二醇、孕酮、睾酮、催乳素、促肾上腺皮质激素和皮质醇）以及刺激后（促黄体生成素、促卵泡生成素、皮质醇、生长激素）的血浆激素测定，以评估CPA的疗效和可能的副作用。青春期临床体征的消退被认为是令人满意的，发育商的增加表明成人身高的预后有所改善。未观察到肾上腺功能不全的症状，但从4名患者对胰岛素低血糖的反应中明显看出CPA具有肾上腺抑制作用。